Cancer-related fatigue is the most prevalent and distressing symptom experienced by patients with advanced cancer. Central nervous system stimulants have been shown to relieve fatigue in nonmalignant disease. Modafinil is a stimulant with a selective site of action in the brain that is better tolerated than traditional stimulants, such as methylphenidate. The aim of this study was to determine the feasibility of conducting a randomised controlled trial to assess the efficacy and safety of modafinil for the treatment of fatigue in patients with lung cancer. Twenty patients with non-small cell lung cancer were recruited to this open-label study. Modafinil was taken in a fixed dose-titration schedule of 100 mg daily for 7 days followed by 200 mg daily for 7 days. Fifteen patients completed the study. During the study period, there was a rapid and statistically significant reduction in the primary outcome, fatigue (P = 0.001) and the secondary outcomes of daytime sleepiness and depression/anxiety. This improvement in fatigue was also clinically significant. Ten patients chose to continue modafinil after the study and the drug was well-tolerated. It would be both feasible and worthwhile to conduct a definitive randomised controlled trial to determine the role of modafinil in the treatment of cancer-related fatigue.
1 Vogelzang N Breitbart W Cella D Curt GA Groopman JE Horning SJ . Patient, caregiver, and oncologist perceptions of cancer-related fatigue: results of a tri-part assessment survey. Semin Hematol1997; 34(Suppl. 2): 4–12.
2.
2 Ashbury FD Findlay H Reynolds B McKerracher K . A Canadian survey of cancer patient experiences; are their needs being met? J Pain Symptom Manage1998; 16: 298–306.
3.
3 Tierney AJ Leonard RC Taylor J Closs SJ Chetty U Rodger A . Side-effects expected and experienced by women receiving chemotherapy for breast cancer. Br Med J1991; 302: 272.
4.
4 Curt GA Breitbart W Cella D Groopman JE Horning SJ Itri LM . Impact of cancer-related fatigue on the lives of patients: new findings from the Fatigue Coalition. Oncologist2000; 5: 353–360.
5.
5 Curt GA . Fatigue in cancer. BMJ2001; 322: 1560.
6.
6 Mock V Pickett M Ropka M Muscari Lin E Stewart KJ Rhodes VA . Fatigue and quality of life outcomes of exercise during cancer treatment. Cancer Pract2001; 9: 19–27.
7.
7 Dimeo FC Stieglitz RD Novelli-Fiscer U Fetscher S Keul J . Effects of physical activity on the fatigue and psychological status of cancer patients during chemotherapy. Cancer1999; 85: 2273–2277.
8.
8 Downer S Joel S Allbright A Plant H Stubbs L Talbot D . A double blind placebo controlled trial of medroxyprogesterone acetate (MPA) in cancer cachexia. Br J Cancer1993; 67: 1102–1105.
9.
9 Bruera E Ernst S Hagen N Spachynski K Belzile M Hanson J . Effectiveness of megestrol acetate in patients with advanced cancer: a double-blind, crossover study. Cancer Prev Control1998; 2: 74–78.
10.
10 Breitbart W Rosenfeld B Kaim M Fundesti-Esch J . A randomised, double-blind, placebo-controlled trial of psychostimulants for the treatment of fatigue in ambulatory patients with human immunodeficiency virus disease. Arch Intern Med2001; 161: 411–420.
11.
11 Weinshenker BG Penman M Bass B Ebers GC Rice GP . A double-blind, randomised, crossover trial of pemoline in fatigue associated with multiple sclerosis. Neurology1992; 42: 1468–1471.
12.
12 Scammell TE Estabrooke IV McCarthy MT Chemelli RM Yanagisawa M Miller MS . Hypothalamic arousal regions are activated during modafinil-induced wakefulness. J Neurosci2000; 20: 8620–8628.
13.
13 Engber TM Koury EJ Dennis SA Miller MS Contreras PC Bhat RV . Differential patterns of regional c-fos induction in the rat brain by amphetamine and the novel wakefulness-promoting agent modafinil. Neurosci Lett1998; 241: 95–98.
14.
14 Buguet A Montmayeur A Pigeau R Naitoh P . Modafinil, d-amphetamine and placebo during 64 hours of sustained mental work. Effects on two nights of recovery sleep. Sleep Res1995; 4: 229–241.
15.
15 Batejat DM Lagarde DP . Naps and modafinil as countermeasure for the effects of sleep deprivation on cognitive performance. Aviat Space Environ Med1999; 70: 493–498.
16.
16 Jasinski DR . An evaluation of the abuse potential of modafinil using methylphenidate as a reference. J Psychopharmacol2000; 14: 53–60.
17.
17 Data on file. Cephalon Study C1538a/303/AP/US/UK. Clinical study report.
18.
18 Data on file. Cephalon UK Ltd. Written summary of clinical safety information; Provigil MAA, 2002.
19.
19 Anonymous. Randomised trial of modafinil as a treatment for the excessive daytime somnolence of narcolepsy: US Modafinil in Narcolepsy Multicentre Study Group. Neurology2000; 54: 1166–1175.
20.
20 Caldwell JA Caldwell JL Smythe NK Hall KK . A double-blind, placebo-controlled investigation of the efficacy of modafinil for sustaining the alertness and performance of aviators: a helicopter simulator study. Psychopharmacology2000; 150: 272–282.
21.
21 Caldwell JA Caldwell JL Smith JK Brown DL . Modafinil’s effects on simulator performance and mood in pilots during 37 hours without sleep. Aviat Space Environ Med2004; 75: 777–784.
22.
22 Pigeau R Naitoh P Buguet A McCann C Baranski J Taylor M . Modafinil, d-amphetamine and placebo during 64 hours of sustained mental work. Effects on mood, fatigue, cognitive performance and body temperature. J Sleep Res1995; 4: 212–218.
23.
23 Baranski JV Pigeau R Dinich P Jacobs I . Effects of modafinil on cognitive and meta-cognitive performance. Hum Psychopharmacol2004; 19: 323–332.
24.
24 Rammohan KW Rosenberg JH Lynn DJ Blumenfeld AM Pollak CP Nagaraja HN . Efficacy and safety of modafinil for the treatment of fatigue in multiple sclerosis; a two centre phase 2 study. J Neurol Neurosurg Psychiatry2002; 72: 179–183.
25.
25 Zifko U Rupp M Schwarz S Zipko HT Maida E . Modafinil in treatment of fatigue in multiple sclerosis. Results of an open-label study. J Neurol2002; 249: 983–987.
26.
26 Cox JM Pappagallo M . Modafinil: a gift to portmanteau. Am J Hosp Palliat Care2001; 18: 408–410.
27.
27 Prommer, E. Modafinil: is it ready for prime time? J Opioid Manage2006; 2: 130–136.
28.
28 National Comprehensive Cancer Network. Cancer-related fatigue. Clinical practice guidelines in oncology. Version 1, 2009. http://www.nccn.org/professionals/physician_gls/PDF/fatigue.pdf
29.
29 Chalder T Berelowitz G Pawlikowska T Watts L Wessely S Wright D . Development of a fatigue scale. J Psychosom Res1993; 37: 763–766.
30.
30 Yellen S Cella DF Webster K Blendowski C Kaplan E . Measuring fatigue and other anaemia-related symptoms with the Functional Assessment of Cancer Therapy (FACT) measurement system. J Pain Symptom Manage1997; 13: 63–74.
31.
31 Johns MW . A new method for measuring daytime sleepiness: the Epworth sleepiness scale. Sleep1992; 15: 376–381.
32.
32 Zigmond AS Snaith RP . The hospital anxiety and depression scale. Acta Psychiatr Scand1983; 67: 361–370.
33.
33 Cella D Eton DT Lei J Peterman A Merkel D . Combining anchor and distribution-based methods to derive minimal clinically important differences on the Functional Assessment of Cancer Therapy (FACT) anaemia and fatigue subscales. J Pain Symptom Manage2002; 24: 547–561.
34.
34 Morrow G Gillies L Hickok J Roscoe JA Padmanaban D Griggs JJ . The positive effect of the psychostimulant modafinil on fatigue from cancer that persists after treatment is completed. J Clin Oncol2005; 23 (16S): 8012.
35.
35 Stone P Richards M A’Hern R Hardy J . A study to investigate the prevalence, severity and correlates of fatigue among patients with cancer in comparison with a control group of volunteers without cancer. Ann Oncol2000; 11: 561–567.
36.
36 Pater JL Zee B Palmer M Johnston D Osoba D . Fatigue in patients with cancer: results with National Cancer Institute of Canada Clinical Trials Group studies employing EORTC QLQ-C30. Support Care Cancer1997; 5: 410–413.
37.
37 National Cancer Research Institute. Lung cancer research in the UK: report of the NCRI Strategic Planning Group on Lung Cancer, London: NCRI, 2006.
38.
38 Stankoff B Waubant E Confavreux C Edan G Debouverie M Rumbach L . Modafinil for fatigue in MS: a randomised placebo-controlled double-blind study. Neurology2005; 64: 1139–1143.
